AlphaStocks
3.9
Weak

BIO-TECHNE Corp (TECH)

Health Care / Life Sciences Tools & Services

S&P 500

$57.95

Scores poorly across most models. Proceed with caution.

Weak

Score based on 4 of 5 models — moderate confidence

#851out of 1123 in Health Care

Is BIO-TECHNE Corp a Good Investment in 2026?

BIO-TECHNE Corp (TECH) scores 3.9 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates BIO-TECHNE Corp as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Top half (rank 40%). BIO-TECHNE Corp currently trades above its estimated fair value of $30, suggesting limited upside at current prices. BIO-TECHNE Corp ranks #851 out of 1123 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E126.1ROE3.7Market Cap9BDiv Yield0.7

Estimated Fair Value

$30.2292% above

Trading above estimated fair value. P/e of 126x implies high growth expectations. eps growth of -56% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Neutral

Significantly above fair value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Top half (rank 40%)

Frequently Asked Questions

Is BIO-TECHNE Corp (TECH) a good investment?
Based on AlphaStocks' composite analysis, BIO-TECHNE Corp (TECH) scores 3.9 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 126x implies high growth expectations. eps growth of -56% may not justify the premium.
What is BIO-TECHNE Corp's Piotroski F-Score?
BIO-TECHNE Corp's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is TECH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $30, TECH appears overvalued. The stock currently trades 92% above its estimated fair value. Trading above estimated fair value. P/e of 126x implies high growth expectations. eps growth of -56% may not justify the premium.
How does TECH compare to other Health Care stocks?
BIO-TECHNE Corp ranks #851 out of 1123 stocks in the Health Care sector, placing it in the top 76% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about TECH?
AlphaStocks evaluates TECH using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Neutral; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 3.9/10.

Similar Stocks

BFAMPARRAZN

Compare TECH with

TECH vs BFAMTECH vs PARRTECH vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer